World Neurosurgery
Volume 73, Issue 1 , Pages 53-62 , January 2010

Rapid malignant transformation of low-grade astrocytomas: report of 2 cases and review of the literature

  • James L. Frazier, MD

      Affiliations

    • Department of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, MD, USA
    • The Johns Hopkins Neuro-Oncology Surgical Outcomes Research Laboratory, Baltimore, MD
    • ,
  • Michael W. Johnson, MD, PhD

      Affiliations

    • Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA
    • ,
  • Peter C. Burger, MD

      Affiliations

    • Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA
    • ,
  • Jon D. Weingart, MD

      Affiliations

    • Department of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, MD, USA
    • ,
  • Alfredo Quinones-Hinojosa, MD

      Affiliations

    • Department of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, MD, USA
    • The Johns Hopkins Neuro-Oncology Surgical Outcomes Research Laboratory, Baltimore, MD
    • Corresponding Author InformationCorresponding author. Brain Tumor Stem Cell Laboratory, Department of Neurosurgery and Oncology, Baltimore, MD 21231, USA. Tel.: +1 410 502 2906; fax: +1 410 502 5559.

Received 9 January 2009 ,Accepted 7 May 2009.

References 

  1. Afra D, Osztie E, Sipos L, Vitanovics D. Preoperative history and postoperative survival of supratentorial low-grade astrocytomas. Br J Neurosurg. 1999;13:299–305
  2. Asari S, Makabe T, Katayama S, Itoh T, Tsuchida S, Ohmoto T. Assessment of the pathological grade of astrocytic gliomas using an MRI score. Neuroradiology. 1994;36:308–310
  3. Barker FG, Chang SM, Huhn SL, et al. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer. 1997;80:936–941
  4. Batchelor TT, Betensky RA, Esposito JM, et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res. 2004;10:228–233
  5. Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer. 1994;74:1784–1791
  6. Berger MS. Surgery of low-grade gliomas—technical aspects. Clin Neurosurg. 1997;44:161–180
  7. Berger MS, Rostomily RC. Low grade gliomas: functional mapping resection strategies, extent of resection, and outcome. J Neurooncol. 1997;34:85–101
  8. Bolender NF, Cromwell LD, Graves V, Margolis MT, Kerber CW, Wendling L. Interval appearance of glioblastomas not evident in previous CT examinations. J Comput Assist Tomogr. 1983;7:599–603
  9. Chamberlain MC, Murovic JA, Levin VA. Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology. 1988;38:1371–1374
  10. Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer. 2005;103:1227–1233
  11. Claus EB, Black PM. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001. Cancer. 2006;106:1358–1363
  12. Cohen-Gadol AA, DiLuna ML, Bannykh SI, Piepmeier JM, Spencer DD. Non-enhancing de novo glioblastoma: report of two cases. Neurosurg Rev. 2004;27:281–285
  13. Earnest FT, Kelly PJ, Scheithauer BW, et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology. 1988;166:823–827
  14. Fujimoto M, Fults DW, Thomas GA, et al. Loss of heterozygosity on chromosome 10 in human glioblastoma multiforme. Genomics. 1989;4:210–214
  15. Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol. 1998;49:436–440
  16. Graif M, Bydder GM, Steiner RE, Niendorf P, Thomas DG, Young IR. Contrast-enhanced MR imaging of malignant brain tumors. AJNR Am J Neuroradiol. 1985;6:855–862
  17. Hammoud MA, Sawaya R, Shi W, Thall PF, Leeds NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol. 1996;27:65–73
  18. Hirose Y, Aldape KD, Chang S, Lamborn K, Berger MS, Feuerstein BG. Grade II astrocytomas are subgrouped by chromosome aberrations. Cancer Genet Cytogenet. 2003;142:1–7
  19. Huncharek M, Kupelnick B. Epidermal growth factor receptor gene amplification as a prognostic marker in glioblastoma multiforme: results of a meta-analysis. Oncol Res. 2000;12:107–112
  20. Johannesen TB, Langmark F, Lote K. Progress in long-term survival in adult patients with supratentorial low-grade gliomas: a population-based study of 993 patients in whom tumors were diagnosed between 1970 and 1993. J Neurosurg. 2003;99:854–862
  21. Kaye AH, Walker DG. Low grade astrocytomas: controversies in management. J Clin Neurosci. 2000;7:475–483
  22. Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg. 2001;95:735–745
  23. Kelly PJ. Surgical issues in the management of supratentorial low-grade gliomas. Clin Neurosurg. 1995;42:399–436
  24. Kimmelman AC, Ross DA, Liang BC. Loss of heterozygosity of chromosome 10p in human gliomas. Genomics. 1996;34:250–254
  25. Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J Neurosurg. 1993;79:533–536
  26. Leighton C, Fisher B, Bauman G, et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol. 1997;15:1294–1301
  27. Lote K, Egeland T, Hager B, Skullerud K, Hirschberg H. Prognostic significance of CT contrast enhancement within histological subgroups of intracranial glioma. J Neurooncol. 1998;40:161–170
  28. Maher EA, Brennan C, Wen PY, et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res. 2006;66:11502–11513
  29. Martin C, Alexander E, Wong T, Schwartz R, Jolesz F, Black PM. Surgical treatment of low-grade gliomas in the intraoperative magnetic resonance imager. Neurosurg Focus. 1998;4:e8
  30. Nagpal J, Jamoona A, Gulati ND, et al. Revisiting the role of p53 in primary and secondary glioblastomas. Anticancer Res. 2006;26:4633–4639
  31. Nakamura M, Konishi N, Tsunoda S, et al. Analysis of prognostic and survival factors related to treatment of low-grade astrocytomas in adults. Oncology. 2000;58:108–116
  32. Nikas DC, Bello L, Zamani AA, Black PM. Neurosurgical considerations in supratentorial low-grade gliomas: experience with 175 patients. Neurosurg Focus. 1998;4:e4
  33. Okamoto K, Ito J, Takahashi N, et al. MRI of high-grade astrocytic tumors: early appearance and evolution. Neuroradiology. 2002;44:395–402
  34. Perez-Cruet MJ, Adelman L, Anderson M, Roth PA, Ritter AM, Saris SC. CT-guided stereotactic biopsy of nonenhancing brain lesions. Stereotact Funct Neurosurg. 1993;61:105–117
  35. Philippon JH, Clemenceau SH, Fauchon FH, Foncin JF. Supratentorial low-grade astrocytomas in adults. Neurosurgery. 1993;32:554–559
  36. Piepmeier JM, Christopher S, Spencer DD, et al. Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. Neurosurgey. 1996;38:872–878
  37. Pierallini A, Bonamini M, Bozzao A, et al. Supratentorial diffuse astrocytic tumours: proposal of an MRI classification. Eur Radiol. 1997;7:395–399
  38. Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with radiotherapy. Int J Radiat Oncol Biol Phys. 1994;28:405–413
  39. Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe?. Ann Neurol. 1992;31:431–436
  40. Schmidt MH, Berger MS, Lamborn KR, et al. Repeated operations for infiltrative low-grade gliomas without intervening therapy. J Neurosurg. 2003;98:1165–1169
  41. Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology. 2002;59:947–949
  42. Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol. 2002;20:2267–2276
  43. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003;63:6962–6970
  44. Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst. 2001;93:1246–1256
  45. Tada K, Shiraishi S, Kamiryo T, et al. Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patient age and survival. J Neurosurg. 2001;95:651–659
  46. van Veelen ML, Avezaat CJ, Kros JM, van Putten W, Vecht C. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery. J Neurol Neurosurg Psychiatry. 1998;64:581–587
  47. Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology. 1992;34:463–469
  48. Wiencke JK, Zheng S, Jelluma N, et al. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol. 2007;9:271–279
  49. Yeh SA, Ho JT, Lui CC, Huang YJ, Hsiung CY, Huang EY. Treatment outcomes and prognostic factors in patients with supratentorial low-grade gliomas. Br J Radiol. 2005;78:230–235

PII: S0090-3019(09)00442-X

doi: 10.1016/j.surneu.2009.05.010

World Neurosurgery
Volume 73, Issue 1 , Pages 53-62 , January 2010

Article Tools

* Image Usage & Resolution